- We still don't know teva-abt launch date agreement. $1.6b total market. royalty 7.5-10%
- two new trial to initiate 1h2013 same co primary endpoints and key secondary, but some design changes with goal of decreasing placebo response
- over 7000 patient-years in LibiGel safety trial now
- this is first public disclosure of specific changes that they are seeking via SPA with FDA
- daily diary was also used unsuccessfully by B-I for flibanserin
- we will not proceed if FDA will not let us switch to less frequent diary
- next safety report by the end of august (9th unblinded look) with top-line safety data 4q-2012
- patent thru year-end 2028 (method of use) and 2022 (formulation)
- sexual dysfunction is the #1 complaint in gynecologist's office
- [rehash of old GVAX cancer vaccine data]
- ~$40m net cash 3/31/2012, report results in new few weeks.
- We hope for SPA agreement in 4q-2012 with FDA
- no Question and answer session on webcast